MD Anderson Board of Visitors welcomes new members, honors new Life Member
HOUSTON ― The University of Texas MD Anderson Cancer Center is pleased to announce six new members to the MD Anderson Cancer Center Board of Visitors (BOV), the institution’s nonfiduciary advisory board. MD Anderson also recognized long-term board member, Nancy Kinder, of Houston, with the BOV’s most prestigious title of Life Member.
“We are honored to welcome six remarkable new members to our board. They are driven by our...
Leading cancer research centers reinforce importance of safe and effective HPV vaccination to prevent cancer
62 NCI-designated cancer centers, leading national organizations and the University of Puerto Rico Comprehensive Cancer Center jointly endorse...
MD Anderson and Nature to co-host conference on the tumor ecosystem
Free, in-person conference runs from Nov. 19-21, 2025
Interested researchers can submit abstracts for consideration by Sept. 19, 2025
Topics...
MD Anderson and Phoenix SENOLYTIX announce strategic cross-licensing agreement to enhance inducible switch technologies for cell and gene therapies
Agreement focuses on rimiducid, an agent used to activate certain safety switch technologies in cell therapies
Phoenix receives a supply of rimiducid and support to seek regulatory approval of a new proprietary injectable formulation, retaining exclusive rights for use in its novel in vivo gene therapy programs
MD Anderson receives rights to the new formulation of rimiducid for use with its inducible switches exclusively in ex vivo cell...
